FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to obstetrics and gynaecology, and can be used for prediction of preeclampsia development. In period of 19–21 weeks, blood glucose level, age, number of pregnancies in anamnesis are determined, presence of chronic arterial hypertension, pulsation index of uterine arteries, sFlt-1 level, average BP, time elapsed since the last delivery, body weight index, presence of thrombocytopenia, ASAT level and calculating a prognostic index of hypertensive disorders of pregnant women of the second trimester (PIHDP2) by formula. If PIHDP2 is 0.215 and more, a high risk of developing preeclampsia is predicted, and if PIHDP2 is less than 0.215, a low risk of developing preeclampsia is predicted.
EFFECT: method enables higher efficiency of prediction of development of preeclampsia by assessing the complex of the most significant indicators.
1 cl, 3 dwg, 2 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF PREDICTING THE DEVELOPMENT OF HYPERTENSIVE DISORDERS DURING PREGNANCY IN THE MIDDLE RISK GROUP AMONG THE WOMEN WHO UNDERWENT COMBINED SCREENING OF THE 1ST TRIMESTER | 2023 |
|
RU2803010C1 |
| METHOD OF PREDICTING THE RISK OF PRE-ECLAMPSIA IN PREGNANT WOMEN WITH TYPE 2 DIABETES MELLITUS | 2022 |
|
RU2800716C1 |
| METHOD FOR PREDICTION OF SEVERE PREECLAMPSIA | 2020 |
|
RU2739694C1 |
| METHOD OF PREDICTING THE RISK OF PRE-ECLAMPSIA IN PREGNANT WOMEN WITH TYPE 1 DIABETES MELLITUS | 2022 |
|
RU2800717C1 |
| METHOD FOR PREDICTING EFFECTIVENESS OF TREATMENT OF MODERATE PREECLAMPSIA | 2020 |
|
RU2752715C1 |
| METHOD FOR PREDICTING THE RISK OF DEVELOPING PREECLAMPSIA BASED ON MOLECULAR GENETIC ANALYSIS | 2021 |
|
RU2775433C1 |
| METHOD FOR FORMING RISK GROUP OF PRE-ECLAMPSIA | 2021 |
|
RU2762204C1 |
| METHOD FOR PREDICTING THE RISK OF DEVELOPING PREECLAMPSIA BASED ON GENETIC TESTING | 2021 |
|
RU2775434C1 |
| METHOD FOR PREDICTING EARLY PREECLAMPSIA ACCORDING TO THE LEVEL OF PROCOAGULANT ACTIVITY OF TISSUE FACTOR IN BLOOD PLASMA AT 19-21 WEEKS OF GESTATION IN PATIENTS OF THE LOW-RISK GROUP | 2022 |
|
RU2795083C1 |
| PREDICTION OF PREECLAMPSIA BASED ON DETERMINING EXTRACELLULAR FETAL DNA IN MATERNAL BLOOD WHEN SCREENING THE FIRST TRIMESTER OF PREGNANCY | 2019 |
|
RU2697845C1 |
